Stocks Under 10 Based on Data Mining: Returns up to 802.61% in 1 Year

Stocks Under 10

This forecast is part of the Stocks Under 10 Dollars Package, as one of I Know First’s forecast services. The full package includes daily stock predictions for a total of 20 Stocks Under 10 with bullish and bearish signals:

  • Top 10 stocks for the long position
  • Top 10 stocks for the short position


Package Name: Stocks Under $10
Recommended Positions: Long
Forecast Length: 1 Year (2/23/20 – 2/23/21)
I Know First Average: 277.81%
Stocks Under 10
Stocks Under 10 chart

In this 1 Year forecast for the Stocks Under $10 Package, there were many high performing trades and the algorithm correctly predicted 8 out 10 trades. The highest trade return came from CLDX, at 802.61%. FCEL, and NLS had notable returns of 581.35% and 491.93%. The overall average return in this Stocks Under $10 package was 277.81%, providing investors with a 261.52% premium over the S&P 500’s return of 16.29% during the same period.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.